Zongertinib (Hernexeos) — Coverage Criteria for HER2‑mutant NSCLC
Customize your policy alerts
Sign up for mhn Policy CP.PHAR.750 alerts
Get alerted when Policy CP.PHAR.750 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity and prior authorization criteria for zongertinib (Hernexeos) for adults with unresectable or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) activating mutations; applies to Centene-affiliated health plans including Commercial, HIM, and Medicaid.
Removed requirement for prior systemic therapy in FDA approved indications and removed 'failure of a prior systemic therapy' requirement in initial approval criteria to reflect expanded indication per prescribing information.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.